The four are not in order. That is a description of where the averages sit, not a view about what happens next.
Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.
The base has run 3.2 weeks and fell 21% from its ceiling at its deepest. The pivot is $16.41, and the stock closed 7.9% below it. Its relative strength rating is 99.
Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.
Nothing dated in the next three months that we can ingest automatically.
On average 6.6% either way across its last 8 reports.
Checking your subscription…
Close before the report day to close after it, so it holds whether the company reported before the open or after the close.
No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.
Held by 1 of 46 tracked funds at the end of Q3 2026.
Last quarter: 1 bought new.
Checking your subscription…
From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.
3 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.
These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.
Checking your subscription…
Checking your subscription…
The most recent of 3 completed bases.
Checking your subscription…